Abstract | BACKGROUND: METHODS: A decision analytical model compared genotype-guided aspirin use versus no genetic testing, no aspirin. The model simulated 100,000 adults ≥50 years of age with average colorectal cancer and cardiovascular disease risk. Low-dose aspirin daily starting at age 50 years was recommended only for those with a genetic test result indicating a greater reduction in colorectal cancer risk with aspirin use. The primary outcomes were quality-adjusted life-years (QALY), costs, and incremental cost-effectiveness ratio (ICER). RESULTS: The mean cost of using genotype-guided aspirin was $187,109 with 19.922 mean QALYs compared with $186,464 with 19.912 QALYs for no genetic testing, no aspirin. Genotype-guided aspirin yielded an ICER of $66,243 per QALY gained, and was cost-effective in 58% of simulations at the $100,000 willingness-to-pay threshold. Genotype-guided aspirin was associated with 1,461 fewer polyps developed, 510 fewer colorectal cancer cases, and 181 fewer colorectal cancer-related deaths. This strategy prevented 1,078 myocardial infarctions with 1,430 gastrointestinal bleeding events, and 323 intracranial hemorrhage cases compared with no genetic testing, no aspirin. CONCLUSIONS: IMPACT:
|
Authors | Eman Biltaji, Brandon Walker, Trang H Au, Zachary Rivers, Jennifer Ose, Christopher I Li, Diana I Brixner, David D Stenehjem, Cornelia M Ulrich |
Journal | Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
(Cancer Epidemiol Biomarkers Prev)
Vol. 30
Issue 6
Pg. 1106-1113
(06 2021)
ISSN: 1538-7755 [Electronic] United States |
PMID | 33849967
(Publication Type: Journal Article, Research Support, N.I.H., Extramural)
|
Copyright | ©2021 American Association for Cancer Research. |
Chemical References |
|
Topics |
- Aspirin
(administration & dosage, economics, pharmacokinetics)
- Colorectal Neoplasms
(economics, epidemiology, genetics, prevention & control)
- Computer Simulation
- Cost-Benefit Analysis
(statistics & numerical data)
- Dose-Response Relationship, Drug
- Feasibility Studies
- Genetic Testing
(economics, statistics & numerical data)
- Genotype
- Humans
- Middle Aged
- Models, Economic
- Myocardial Infarction
(economics, epidemiology, genetics, prevention & control)
- Pharmacogenomic Variants
- Precision Medicine
(economics, methods)
- Primary Prevention
(economics, methods)
- Quality-Adjusted Life Years
|